Salix’s UCERIS Granted Tentative FDA Approval for Distal Ulcerative Colitis

Salix’s UCERIS Granted Tentative FDA Approval for Distal Ulcerative Colitis
Salix Pharmaceuticals may soon bring a new treatment for mild-to-moderate distal ulcerative colitis to the market with its tentative Food and Drug Administration (FDA) approval for UCERIS (budesonide) rectal foam. The product, which is a rectally-administered corticosteroid foam, addresses limitations of other currently approved therapies. “The unique delivery system of UCERIS rectal foam can help

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *